GlassScriptPhysician profile
Thomas Carl Krivak
NPI 1609840057
$1,636,014.82
in general payments reported to CMS, 2019-2025
28 companies · $314K in 2025
The $314K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346K · 2020: $66K · 2021: $160K · 2022: $209K · 2023: $218K · 2024: $324K · 2025: $314K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $598K · Consulting Fee: $116K · Travel and Lodging: $107K · Food and Beverage: $17K · Honoraria: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,168 · Education: $18.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $598,411.00 |
| Consulting Fee | $115,891.75 |
| Travel and Lodging | $107,066.87 |
| Food and Beverage | $16,789.17 |
| Honoraria | $14,525.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,167.50 |
| Education | $18.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $608,662.38 | 2019-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $334,079.50 | 2020-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $148,699.85 | 2019-2025 | Keytruda, Lynparza |
| Tesaro, INC. | $109,971.83 | 2019 | |
| Genmab U.S., INC. | $104,413.17 | 2021-2025 | Tivdak |
| Abbvie INC. | $81,985.70 | 2019-2025 | |
| Pfizer INC. | $50,883.51 | 2024-2025 | |
| Seagen INC. | $37,452.31 | 2022-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $34,301.48 | 2020-2024 | Mychoice Cdx, Myrisk |
| Immunogen, INC. | $33,191.19 | 2023-2024 | Elahere, Elahere |
| Genentech USA, INC. | $21,522.26 | 2019 | |
| Daiichi Sankyo INC. | $20,902.60 | 2025 | Enhertu |
| Eisai INC. | $13,347.26 | 2022-2025 | |
| Clovis Oncology, INC. | $11,638.01 | 2019-2022 | |
| Medtronic, INC. | $11,198.88 | 2024-2025 | Auto Suture, Ligasure |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biom'Up Sa | $6,987.26 | 2019 | |
| Biontech Se | $2,160.00 | 2025 | |
| Novocure INC. | $2,140.00 | 2019 | |
| Karyopharm Therapeutics INC. | $873.61 | 2023-2025 | Xpovio |
| Coopersurgical, INC. | $513.16 | 2019-2023 | Seeclear Xcl Laparoscopic Smoke Evacuation System |
| Caris Mpi, INC. | $328.60 | 2025 | Mi Cancer Seek |
| Stryker Corporation | $310.18 | 2025 | Pro-Dense, Triathlon |
| Corcept Therapeutics | $251.99 | 2025 | Korlym |
| Foundation Medicine, INC. | $104.64 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $80.74 | 2025 | Libtayo |
| Roche Diagnostics Corporation | $14.71 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Krivak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.